ClinicalTrials.gg
RecruitingNCT07898137Updated Oct 27, 2026

Pharmacokinetic (PK) Study of Phytochemicals in Whole Grains (WGs)- Brown Rice

An interventional study of Whole-Grain Brown Rice and Refined White Rice in Healthy Adult Males and Healthy Adult Females, sponsored by North Carolina Agriculture & Technical State University. Recruiting at 1 site in United States. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by North Carolina Agriculture & Technical State University · Not applicable, Interventional, and Basic science

Updated Oct 27, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

The purpose of this research study is to identify biomarkers (measurable signs).

in the body like substances in blood or urine) of whole-grain (WG) brown rice intake following an acute exposure in a pharmacokinetic (how the body absorbs, processes, and gets rid of a substance or ingredient) feeding study. In this aim, investigators will conduct a randomized crossover acute pharmacokinetic study of brown rice. Investigators will then use a targeted metabolomics approach to identify the exposure markers of brown rice intake, further develop analytical methods to study its pharmacokinetics, build an in-house WG metabolite database, and use an untargeted metabolomics approach to investigate postprandial biomarkers of brown rice intake. At the completion of this study, the expectation is that investigators will identify brown rice phytochemicals and its metabolites as objective biomarkers of total and individual WGs that are commonly consumed by Americans.

Read the detailed description

Days 0-7: Healthy volunteers were recruited and instructed to avoid consuming any whole-grain products beginning one week before the intervention and continuing throughout the study period.

Day 8 - Pharmacokinetic (PK) Visit 1: Participants consumed two servings of either whole-grain or refined-grain (46 g of raw grain per serving; 92 g total).Blood and urine samples were collected at multiple time points over 48 hours, and baseline fecal samples were collected the day before the intervention.

Day 15 - Pharmacokinetic (PK) Visit 2: After a 6-day washout period, participants crossed over to the alternate treatment. Blood and urine samples were again collected at multiple time points over 48 hours.

02

Conditions studied

  • Healthy Adult Males
  • Healthy Adult Females
03

In context

Lead sponsor

North Carolina Agriculture & Technical State University is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 25-70 years
  • (BMI) between 18 and 30 kg/m²
  • Able to read, speak, and understand English
  • No known allergy or intolerance to the test foods
  • Normal blood and urine biochemical parameters
  • No antibiotic use within the past 6 months
  • Willing and able to comply with all study procedures, including dietary restrictions throughout the study period
  • No medical conditions or lifestyle factors that, in the opinion of the investigators, would interfere with the study objectives

Exclusion criteria

Exclusion Criteria:

  • Active disease, including gout, heart disease, peripheral vascular disease, kidney disease, liver disease, cancer, diabetes, gastrointestinal disorders, or endocrine disorders that may interfere with the study
  • Current smoker or use of tobacco products
  • Unwilling or unable to comply with the required dietary restrictions during the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Whole-Grain brown rice → Refined white rice

    Participants will complete a 7-day wash-in period during which they will avoid consuming whole-grain products. During Pharmacokinetic (PK) Visit 1 (Day 8), participants will consume whole-grain brown rice. After a 6-day washout period, participants will cross over and consume refined white rice during PK Visit 2 (Day 15). Blood and urine samples will be collected over 48 hours following each intervention.

    Dietary Supplement: Whole-Grain Brown Rice · Dietary Supplement: Refined White Rice

  • Experimental
    Refined white rice → Whole-Grain brown rice

    Participants will complete a 7-day wash-in period during which they will avoid consuming whole-grain products. During Pharmacokinetic (PK) Visit 1 (Day 8), participants will consume refined white rice. After a 6-day washout period, participants will cross over and consume whole-grain brown rice during PK Visit 2 (Day 15). Blood and urine samples will be collected over 48 hours following each intervention.

    Dietary Supplement: Whole-Grain Brown Rice · Dietary Supplement: Refined White Rice

Interventions

  • Dietary supplementWhole-Grain Brown Rice

    Participants will consume two servings of cooked whole-grain brown rice (46 g raw grain per serving; 92 g total) during the pharmacokinetic study visit.

  • Dietary supplementRefined White Rice

    Participants will consume two servings of cooked refined white rice (46 g raw grain per serving; 92 g total) during the pharmacokinetic study visit.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma and Urine Metabolite Concentration Following Whole-Grain Product Intake

    Metabolite concentrations will be measured at baseline and at postprandial time points following consumption of the whole-grain products using untargeted and targeted metabolomics. Changes from baseline in metabolite concentrations will be reported to characterize the acute metabolic response to whole-grain products.

    Time frame: Baseline through 48 hours after consumption of whole-grain product during pharmacokinetic study visit.

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07898137
Lead sponsor
North Carolina Agriculture & Technical State University
Responsible party
Shengmin Sang (Distinguished Professor, North Carolina Agriculture & Technical State University) — Principal investigator
First posted
Oct 27, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
May 15, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Shengmin Sang
Contact
ssang@ncat.edu
704-250-5710

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion